Charles Pitman CFA
Stock Analyst at Barclays
(4.52)
# 981
Out of 4,411 analysts
360
Total ratings
61.6%
Success rate
13.5%
Average return
Main Sectors:
Stocks Rated by Charles Pitman CFA
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SWX: PPGN PolyPeptide Group AG | Maintained: Buy | CHF 33.00 → CHF 40.00 | $35.55 | +12.52% | 6 | Jun 16, 2026 | |
| LON: 0NZT UCB SA | Downgraded: Hold | €310.00 → €300.00 | $253.18 | +18.49% | 131 | Jun 12, 2026 | |
| SWX: BANB Bachem Holding AG | Maintained: Hold | CHF 65.00 → CHF 70.00 | $65.65 | +6.63% | 12 | Jun 9, 2026 | |
| ETR: BAYN Bayer Aktiengesellschaft | Maintained: Buy | €48.00 → €50.00 | $36.01 | +38.85% | 15 | May 19, 2026 | |
| ETR: MRK Merck KGaA | Maintained: Hold | €130.00 | $132.05 | -1.55% | 18 | May 18, 2026 | |
| SWX: LONN Lonza Group AG | Maintained: Buy | CHF 670.00 | $494.40 | +35.52% | 29 | May 11, 2026 | |
| EPA: BIM bioMérieux S.A. | Maintained: Hold | €100.00 → €90.00 | $68.10 | +32.16% | 5 | Apr 23, 2026 | |
| ETR: SRT3 Sartorius Aktiengesellschaft | Maintained: Buy | €270.00 | $230.70 | +17.04% | 22 | Apr 23, 2026 | |
| EPA: DIM Sartorius Stedim Biotech S.A. | Maintained: Buy | €220.00 | $176.30 | +24.79% | 17 | Apr 23, 2026 | |
| BME: GRF Grifols, S.A. | Maintained: Buy | €13.50 → €12.50 | $9.05 | +38.12% | 17 | Apr 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | CHF 75.00 | $66.82 | +12.24% | 1 | Mar 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | €48.00 | $50.60 | -5.14% | 15 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $10.38 | - | 1 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $367.00 | - | 1 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | €105.00 → €60.00 | $66.44 | -9.69% | 3 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €700.00 → €850.00 | $764.00 | +11.26% | 26 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | €120.00 → €125.00 | $155.50 | -19.61% | 30 | Oct 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $673 → $754 | $878.49 | n/a | 9 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $21 | $7.59 | n/a | 1 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $222.47 | n/a | 1 | Jan 13, 2022 |
PolyPeptide Group AG
Jun 16, 2026
Maintained: Buy
Price Target: CHF 33.00 → CHF 40.00
Current: $35.55
Upside: +12.52%
UCB SA
Jun 12, 2026
Downgraded: Hold
Price Target: €310.00 → €300.00
Current: $253.18
Upside: +18.49%
Bachem Holding AG
Jun 9, 2026
Maintained: Hold
Price Target: CHF 65.00 → CHF 70.00
Current: $65.65
Upside: +6.63%
Bayer Aktiengesellschaft
May 19, 2026
Maintained: Buy
Price Target: €48.00 → €50.00
Current: $36.01
Upside: +38.85%
Merck KGaA
May 18, 2026
Maintained: Hold
Price Target: €130.00
Current: $132.05
Upside: -1.55%
Lonza Group AG
May 11, 2026
Maintained: Buy
Price Target: CHF 670.00
Current: $494.40
Upside: +35.52%
bioMérieux S.A.
Apr 23, 2026
Maintained: Hold
Price Target: €100.00 → €90.00
Current: $68.10
Upside: +32.16%
Sartorius Aktiengesellschaft
Apr 23, 2026
Maintained: Buy
Price Target: €270.00
Current: $230.70
Upside: +17.04%
Sartorius Stedim Biotech S.A.
Apr 23, 2026
Maintained: Buy
Price Target: €220.00
Current: $176.30
Upside: +24.79%
Grifols, S.A.
Apr 22, 2026
Maintained: Buy
Price Target: €13.50 → €12.50
Current: $9.05
Upside: +38.12%
Mar 11, 2026
Maintained: Hold
Price Target: CHF 75.00
Current: $66.82
Upside: +12.24%
Feb 12, 2026
Upgraded: Hold
Price Target: €48.00
Current: $50.60
Upside: -5.14%
Jan 6, 2026
Upgraded: Buy
Price Target: n/a
Current: $10.38
Upside: -
Jan 6, 2026
Downgraded: Sell
Price Target: n/a
Current: $367.00
Upside: -
Jan 6, 2026
Downgraded: Sell
Price Target: €105.00 → €60.00
Current: $66.44
Upside: -9.69%
Oct 31, 2025
Maintained: Buy
Price Target: €700.00 → €850.00
Current: $764.00
Upside: +11.26%
Oct 24, 2025
Maintained: Hold
Price Target: €120.00 → €125.00
Current: $155.50
Upside: -19.61%
Apr 28, 2025
Maintained: Buy
Price Target: $673 → $754
Current: $878.49
Upside: n/a
Jan 4, 2024
Upgraded: Buy
Price Target: $21
Current: $7.59
Upside: n/a
Jan 13, 2022
Initiated Coverage: Buy
Price Target: n/a
Current: $222.47
Upside: n/a